ArticleFrontiers in endocrinology2026
Pubertal dysfunctions in intracranial germ cell tumors.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pediatric intracranial germ cell tumors (IC-GCTs) are frequently associated with pubertal dysfunctions, either at diagnosis or during follow-up. This study aims to evaluate the prevalence and types of pubertal disorders in a cohort of pediatric patients with IC-GCTs. Methods: We collected clinical, radiological, histopathological, and hormonal data. Pubertal dysfunctions were classified as: (1) pseudo-precocious puberty (PPP, gonadotrophin-independent); (2) central precocious puberty (CPP, gonadotrophin-dependent); (3) hypogonadotrophic hypogonadism (HH). Results: Sixty patients with IC-GCTs (followed-up between 1996 and 2023 at Royal Marsden Hospital, UK) were included (median follow-up 22.9 months). Germinomas represented 70%, teratomas and mixed GCTs 15% each. Tumors were suprasellar (59%), pineal (30%), or bifocal (11%). Treatments included surgery (11%), chemotherapy (78%), and radiotherapy (90%). Pubertal disorders were found in 27 patients (16 males, 11 females). PPP was found in five patients at diagnosis; in three, it resolved with tumor treatment; one required treatment with bicalutamide/anastrozole and one progressed to CPP. Three patients in total developed CPP (one after PPP, one post-PPP with intervening treatment, and one post-cancer treatment completion). HH was diagnosed in 20 cases (mean age 17.5 years in males, 15.1 in females). Two had HH at diagnosis. One female had amenorrhea with polycystic ovary syndrome and responded to combined oral hormonal therapy. No cases of hypergonadotrophic hypogonadism from chemotherapy were observed. Conclusion: Pubertal dysfunctions are common in IC-GCTs, especially with suprasellar involvement. Patterns include PPP, CPP, and HH, which may evolve over time. Long-term specialist endocrine follow-up is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.